ReviewCureus2026
Association Between Smokeless Tobacco Use and Cardiovascular Disease Outcomes: A Systematic Review and Meta-Analysis With Subgroup Evaluation of Nawar-Type Products.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmokeless tobacco (SLT) use remains prevalent globally and is associated with cardiovascular disease (CVD). However, variations in product composition, particularly between Scandinavian snus and alkaline, unfermented preparations such as Nawar, may influence risk profiles.
methodsWe conducted a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. PubMed/MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from January 1990 to December 2024 (final search: December 15, 2024). Observational studies evaluating SLT use and CVD outcomes in adults were included. Sixteen studies met the inclusion criteria, including 14 primary studies and 2 prior meta-analyses. Random-effects models were used to compute pooled odds ratios (ORs). Primary outcomes included composite CVD events (fatal and non-fatal), myocardial infarction (MI), stroke, and CVD mortality.
resultsSLT use was associated with increased CVD risk (pooled OR: 1.45; 95% CI: 1.28-1.64; I² = 47%). Elevated risks were observed for MI (OR: 1.42; 95% CI: 1.21-1.67) and composite CVD outcomes (OR: 1.61; 95% CI: 1.32-1.96). Subgroup analyses showed higher estimates in South and Central Asia (OR: 1.83), though these were based on a limited number of studies. Nawar-type products were represented in a small subset of studies, and their contribution to the pooled estimate was limited relative to mixed SLT and Scandinavian snus cohorts. Sensitivity analyses excluding prior meta-analyses yielded consistent but slightly attenuated estimates.
conclusionsSLT use is associated with a statistically significant increase in CVD risk. While Nawar-type products may confer a higher risk, evidence remains limited and predominantly derived from cross-sectional studies. Large prospective studies in high-prevalence regions are required to clarify product-specific effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.